[DERM] Dermira, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 30.57 Change: 0.63 (2.1%)
Ext. hours: Change: 0 (0%)

chart DERM

Refresh chart

Strongest Trends Summary For DERM

DERM is in the medium-term down -34% in 1 month and down -43% in 3 months. In the long-term down -75% in 2 years and down -81% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-17.27% ROE-20.31% ROI
Current Ratio10.38 Quick Ratio Long Term Debt/Equity0.02 Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40 K Cash From Investing Activities1.86 M Cash From Operating Activities-5.12 M Gross Profit
Net Profit-14.04 M Operating Profit-14.23 M Total Assets165.61 M Total Current Assets124.49 M
Total Current Liabilities12 M Total Debt1.94 M Total Liabilities24.75 M Total Revenue
Technical Data
High 52 week30.93 Low 52 week7.12 Last close9.16 Last change-0.43%
RSI16.72 Average true range0.59 Beta1.06 Volume98.87 K
Simple moving average 20 days-14.58% Simple moving average 50 days-19.03% Simple moving average 200 days-9.46%
Performance Data
Performance Week-15.26% Performance Month-5.66% Performance Quart-15.34% Performance Half-15.19%
Performance Year-66.4% Performance Year-to-date-67.06% Volatility daily3.12% Volatility weekly6.98%
Volatility monthly14.3% Volatility yearly49.53% Relative Volume231.19% Average Volume560.75 K
New High New Low

News

2019-01-17 08:03:49 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-15 08:03:35 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-09 08:03:56 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-08 12:50:13 | At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

2018-12-20 08:04:11 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-12-18 22:28:01 | Do Hedge Funds Love Dermira Inc DERM?

2018-12-17 08:04:24 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-12-11 17:07:35 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-12-05 14:58:37 | Is Dermira Inc’s NASDAQ:DERM CEO Paid At A Competitive Rate?

2018-12-04 07:30:00 | Dermira Enters into Credit Facility with Athyrium Capital Management

2018-11-28 08:40:00 | Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-24 08:03:33 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-11-19 08:00:00 | Dermira to Present at Evercore ISI HealthCONx Conference

2018-11-13 08:03:39 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-11-09 11:27:24 | Edited Transcript of DERM earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-08 16:05:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-11-07 19:00:12 | Dermira DERM Reports Q3 Loss, Lags Revenue Estimates

2018-11-07 16:01:00 | Dermira Reports Third Quarter 2018 Financial Results

2018-10-31 16:01:00 | Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018

2018-10-23 16:01:00 | Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

2018-10-23 08:05:08 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-10-17 07:25:00 | Report: Exploring Fundamental Drivers Behind Dermira, California Resources, OGE Energy, Oasis Petroleum, Harmonic, and CBIZ — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-09 16:01:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-10-08 08:03:37 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-10-02 08:30:00 | Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin

2018-10-01 07:30:00 | Dermira’s QBREXZA™ glycopyrronium Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis

2018-09-25 08:05:10 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-09-25 08:00:00 | Dermira to Present at Cantor 2018 Global Healthcare Conference

2018-09-22 08:05:34 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-09-13 06:00:00 | Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress

2018-09-10 16:02:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-09-05 07:30:00 | Dermira Provides Launch Readiness Update for QBREXZA™ glycopyrronium Cloth for Primary Axillary Hyperhidrosis

2018-09-01 08:01:37 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-08-25 08:04:15 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-08-21 08:04:28 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-08-20 07:50:00 | Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments

2018-08-08 20:14:20 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-08-06 18:05:10 | Dermira DERM Reports Q2 Loss, Tops Revenue Estimates

2018-08-06 17:02:36 | Dermira: 2Q Earnings Snapshot

2018-08-06 16:01:00 | Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update 

2018-07-17 08:03:05 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-07-10 16:01:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-07-06 14:36:06 | Dermira DERM Gains 5% in a Week, Post-Qbrexa Approval

2018-07-02 08:36:12 | Are Options Traders Betting on a Big Move in Dermira DERM Stock?

2018-06-29 14:09:43 | FDA Approval Pushes Dermira’s Stock Price Up

2018-06-29 12:00:00 | Dermira Shares Soar With FDA Approval of New Cloth

2018-06-29 11:38:24 | FDA OKs first drug made to reduce excessive sweating

2018-06-29 08:36:29 | FDA approves Dermira's wipe for excessive armpit sweating

2018-06-29 07:00:00 | Dermira Receives FDA Approval for Qbrexza™ glycopyrronium Cloth to Treat Primary Axillary Hyperhidrosis

2018-06-18 07:20:00 | Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks